PP405, a topical treatment, shows promise for hairgrowth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
2% fucoidan alleviated AGA symptoms, promoted hairgrowth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hairgrowth.
PP405 is not a cure for hair loss but may reactivate dormant hair follicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.
A user in their mid-30s experienced unexpected hairline regrowth after starting a new supplement stack, despite being on a regimen of finasteride, minoxidil, and Nizoral for over four years. The new supplements include Tongkat Ali, Fadogia Agrestis, Panax Red Ginseng, Vitamin B1, Vitamin D3, Zinc Picolinate, Magnesium Glycinate, Maca, and L-Citrulline.